Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.
Otto Simonsson, Simon B. Goldberg, Walter Osika, Cecilia U.D. Stenfors, Sankalp Chaturvedi, Caroline M. Swords, Jayanth Narayanan, Peter S. Hendricks
Psychological Medicine March 31, 2025 DOI: 10.1017/s0033291725000716 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Longitudinal Peer reviewed |
|---|---|
| Sample size | 12,345 |
| Population | Adults with self-reported naturalistic psychedelic use, including those with psychiatric histories of schizophrenia or bipolar I disorder |
| Duration | 2-month study period |
| Topics | Psilocybin |
| Keywords | Psychedelics Mental health research Drug safety Psychiatric symptoms |
| Citations | 16 |
| Key findings | Naturalistic psychedelic use in illegal contexts was associated with increases in psychotic and manic symptoms, moderated by frequency of use, challenging experiences, and psychiatric history. |
Abstract
Background: Findings from contemporary clinical trials suggest that psychedelics are generally safe and may be effective in the treatment of various psychiatric disorders. However, less is known about the risks associated with psychedelic use outside of medically supervised contexts, particularly in populations that are typically excluded from participation in clinical trials.
Methods: =21,990), we investigated associations between self-reported naturalistic psychedelic use and psychotic and manic symptoms, with emphasis on those with psychiatric histories of schizophrenia or bipolar I disorder.
Results: The follow-up survey was completed by 12,345 participants (56% retention), with 505 participants reporting psychedelic use during the 2-month study period. In covariate-adjusted regression models, psychedelic use during the study period was associated with increases in the severity of psychotic and manic symptoms. However, such increases were only observed for those who reported psychedelic use in an illegal context. While increases in the severity of psychotic symptoms appeared to depend on the frequency of use and the intensity of challenging psychedelic experiences, increases in the severity of manic symptoms appeared to be moderated by a personal history of schizophrenia or bipolar I disorder and the subjective experience of insight during a psychedelic experience.
Conclusions: The findings suggest that naturalistic psychedelic use specifically in illegal contexts may lead to increases in the severity of psychotic and manic symptoms. Such increases may depend on the frequency of use, the acute subjective psychedelic experience, and psychiatric history.
Comparable studies
Other observational and cohort studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Patients with treatment-resistant depression | 2017 | Observational cohort | n = 19 |
| Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels Healthy volunteers | 2019 | Observational cohort | n = 8 |
| Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin Humans | 2017 | Observational study | |
| Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. USA adult respondents from the National Survey on Drug Use and Health (2008-2012) | 2015 | Observational cohort | n = 190,000 |
| Prediction of Psilocybin Response in Healthy Volunteers Healthy volunteers | 2012 | Observational cohort | n = 409 |
Citations in the library
Cited by 17
- The science of psychedelic medicine. Nature Medicine February 6, 2026
- Naturalistic psychedelic use and changes in depressive symptoms. Journal of Affective Disorders July 9, 2025
- Psychedelic medicine: mechanisms, evidence, and translation to practice BMJ February 23, 2026
- Persistent Altered States: Psychological Treatment of Psychedelic Adverse Effects Tidsskrift for Norsk psykologforening December 1, 2025
- How to set up a psychedelic study: Unique considerations for research involving human participants. Neuroscience & Biobehavioral Reviews July 1, 2026
and 12 more in the library
Cites 28
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
and 23 more in the library